about
Effects of neurokinin-1 receptor agonism and antagonism in the rostral ventromedial medulla of rats with acute or persistent inflammatory nociceptionEFNS guideline on the drug treatment of migraine - report of an EFNS task forceMigraine pathogenesis and state of pharmacological treatment optionsNeurokinin-1-receptor antagonism decreases anxiety and emotional arousal circuit response to noxious visceral distension in women with irritable bowel syndrome: a pilot studyPlacebo response in the prophylaxis of migraine: a meta-analysis.RPR100893, a substance-P antagonist, is not effective in the treatment of migraine attacks.Pearls and pitfalls in experimental in vivo models of migraine: dural trigeminovascular nociception.Finding new drug targets for the treatment of migraine attacks.Novel therapies in the treatment of irritable bowel syndrome.Substance P induces adverse myocardial remodelling via a mechanism involving cardiac mast cells.Substance P in heart failure: the good and the bad.New migraine and pain research.Blocking neurogenic inflammation for the treatment of acute disorders of the central nervous system.Medullary pain facilitating neurons mediate allodynia in headache-related painAnimal models of headache: from bedside to bench and back to bedside.5-HT(1F) Receptor agonists: a new treatment option for migraine attacks?Role of spinal neurotransmitter receptors in itch: new insights into therapies and drug development.Chemical mediators of migraine: preclinical and clinical observations.Insights into the pharmacological targeting of the trigeminocervical complex in the context of treatments of migraine.Animal migraine models for drug development: status and future perspectives.Efficacy and mechanism of anticonvulsant drugs in migraine.Therapeutic prospects for migraine: can paradise be regained?An update on migraine: current understanding and future directions.Pathophysiology of Migraine: A Disorder of Sensory Processing.Imaging drugs with and without clinical analgesic efficacy.From receptor binding kinetics to signal transduction; a missing link in predicting in vivo drug-action.Octreotide is not effective in the acute treatment of migraine.Migraine relief by chilis and other alternative medications: evidence indicates a central role for trp channels.Tactile-induced ultrasonic vocalization in the rat: a novel assay to assess anti-migraine therapies in vivo.The effects of ibuprofen and the neurokinin-1 receptor antagonist GR205171A on Fos expression in the ferret trigeminal nucleus following tooth pulp stimulation.Neurovascular mechanisms of migraine and cluster headache.Bench to bedside advances in the 21st century for primary headache disorders: migraine treatments for migraine patients.Dural neurogenic inflammation induced by neuropathic pain is specific to cranial region.PACAP and migraine headache: immunomodulation of neural circuits in autonomic ganglia and brain parenchyma.Glutamate and Its Receptors as Therapeutic Targets for Migraine.
P2860
Q24654992-E18BF269-953B-4F12-841F-8FA097607374Q28219436-8E92B070-03B9-4708-9C9F-F93BED6FE8DBQ30886663-F27E199A-48F3-4219-8AC7-E68CC42B4825Q33815691-C3B94A3E-3A6F-482F-B985-A19AAC7C62A9Q34621702-A9CA3498-0476-434D-926A-2AF6BB4C5750Q34648375-44435FD1-70BA-4CB3-9729-EC2D4344B29CQ34720188-086D3A73-4487-40B7-B01A-9E9D5367CA80Q34954050-B81C5F44-09A3-4726-8ADB-9414C44F8B56Q35094684-B498133E-B93D-452F-BC89-A9575DFA2781Q35538215-ACB6D0D9-03D5-49BC-B0CD-31B1F789E7D3Q35670008-C731BF33-461D-460B-9EDA-766BFFE88EE6Q36787453-06B33CD8-F342-4D0B-9527-112225B97170Q36925594-7F28EF78-156C-47BA-AE5F-5B15F60E5A29Q37409407-F143700C-8F9B-4A99-99B6-1B24DBCC790BQ37699421-B9894F86-04F9-46EC-8A39-98AACA8E295AQ37739587-3AE37214-0D03-48FE-A9AC-2C8BEA68AA88Q37800506-034CEC1C-3BB6-4E9B-B546-F51A1C0BFA56Q37883455-A5CE6B65-7EB0-46FA-9072-E68173794962Q38129436-C4E670FB-683F-4904-B0ED-089ECE4E7C4DQ38162801-A46ADB66-0D05-46DD-9B68-90890F545069Q38185096-33C527F0-DE16-47D4-9085-1D3F5824101AQ38392414-E1A7912A-77A2-4EB3-ADFD-AD933442FAEBQ38742593-20663737-2747-4319-A4C1-1324A1E790BCQ39127073-19C1D4B4-107D-4B4A-8437-B59C5A0AAE61Q39596370-C8A9731D-0FAB-4E1F-AB62-8847F96E79C6Q42620551-F5D8DFA4-CAD8-4EB4-8F20-00EB3D0178CEQ45192198-4A21AAD5-AE98-468B-8C76-BFF7FC7BA1EFQ45732621-D28B8642-299F-484C-A6F9-F39FE4F6CCCCQ46580205-6888B7A8-ECD2-4E66-97BB-A3877A43944EQ46980234-E70A4EF6-C43A-4659-BF01-3CA4C2F0D101Q47758217-70C74A0B-4E0E-4D52-8CA4-32A7202B449EQ48495487-A85466AE-810C-4860-B4D0-890B256EB3EAQ50227033-5F68E6EB-0E2A-498B-9327-1F3FC9BC6E02Q52656846-9E7C7E17-FAEE-4245-AC6E-7508A1671094Q52672731-DA189ECF-36C1-4642-82E6-B374414D0386
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Lanepitant, an NK-1 antagonist, in migraine prevention.
@ast
Lanepitant, an NK-1 antagonist, in migraine prevention.
@en
type
label
Lanepitant, an NK-1 antagonist, in migraine prevention.
@ast
Lanepitant, an NK-1 antagonist, in migraine prevention.
@en
prefLabel
Lanepitant, an NK-1 antagonist, in migraine prevention.
@ast
Lanepitant, an NK-1 antagonist, in migraine prevention.
@en
P2093
P1433
P1476
Lanepitant, an NK-1 antagonist, in migraine prevention.
@en
P2093
D J Goldstein
K W Johnson
L A Phebus
P Hipskind
P304
P356
10.1046/J.1468-2982.2001.00161.X
P407
P577
2001-03-01T00:00:00Z